Status:
WITHDRAWN
The Influence of Ezetimibe on Gallbladder Function
Lead Sponsor:
Indiana University
Conditions:
Chronic Acalculous Cholecystitis
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Ezetimibe is a drug which inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Ezetimibe has been approved for use in humans to lower serum cholesterol. The primary...
Detailed Description
Gallbladder disease continues to be a major healthcare problem in the United States with more than 750,000 cholecystectomies being performed each year. In the last decade, the proportion of elective c...
Eligibility Criteria
Inclusion
- Subjects with typical biliary pain and ejection fraction \<30% on a HIDA scan.
- Must be \> 18 years of age.
Exclusion
- Subjects with gallstones seen on HIDA.
- Subjects on statin medication
- Subjects with known allergies to ezetimibe.
- Subjects who are pregnant or breast-feeding.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00634140
Start Date
August 1 2009
End Date
August 1 2009
Last Update
March 30 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Hospital
Indianapolis, Indiana, United States, 46202